Inhibrx, Inc. Common Stock
INBX
INBX was delisted on the 29th of May, 2024.
127 hedge funds and large institutions have $1.55B invested in Inhibrx, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 33 increasing their positions, 42 reducing their positions, and 13 closing their positions.
3,377% more call options, than puts
Call options by funds: $46.8M | Put options by funds: $1.34M
123% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 13
117% more capital invested
Capital invested by funds: $716M → $1.55B (+$836M)
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
14% more funds holding
Funds holding: 111 → 127 (+16)
21% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$17M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$12.4M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$5.34M |
| 4 |
Millennium Management
New York
|
+$4.9M |
| 5 |
Morgan Stanley
New York
|
+$4.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$11.4M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$10.9M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$7.96M |
| 4 |
JP Morgan Chase
New York
|
-$6.82M |
| 5 |
Two Sigma Investments
New York
|
-$4.28M |
INBX Hedge Fund Activity: Q4 2023 in Review
127 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Inhibrx, Inc. Common Stock (INBX) for Q4 2023, worth a combined $1.55B — up 117% from $716M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new INBX positions and 13 closed out — a net gain of 16 holders — while 33 added to existing stakes and 42 trimmed.
The largest buyer was Woodline Partners, adding an estimated $17M. The largest seller was Soleus Capital Management, cutting an estimated $11.4M.
- 127 institutional investors held Inhibrx, Inc. Common Stock (INBX) as of Q4 2023, up from 111 in Q3 2023.
- Funds reported $1.55B of Inhibrx, Inc. Common Stock stock for Q4 2023, up 117% quarter-over-quarter.
- 29 funds opened new Inhibrx, Inc. Common Stock positions in Q4 2023 and 13 closed out, a net change of +16 holders.
- The largest Inhibrx, Inc. Common Stock buyer in Q4 2023 was Woodline Partners, an estimated $17M added.
- The largest Inhibrx, Inc. Common Stock seller in Q4 2023 was Soleus Capital Management, an estimated $11.4M sold.
Based on aggregated 13F filings for Q4 2023.